TRASTUZUMAB (Herceptin) prior authorization at Highmark
Submission criteria, P2P prep, and appeal path if denied — for prescribers and PA staff
Highmark requires HER2/neu Receptor Antagonist prior-authorization documentation for TRASTUZUMAB (Herceptin): a diagnosis with ICD-10 code, documented step-therapy history, and prescriber attestation of medical necessity. Standard PA decisions return on the clock printed in the current member-specific payer source; if denied, use the appeal window printed on the denial notice to appeal.
The PA criteria you'll need to meet
Highmark reviews TRASTUZUMAB (Herceptin) prior authorizations against its medical policy for HER2/neu Receptor Antagonist. Highmark-specific context: Operates BCBS in PA (western), WV, DE, NY (western). Owns Allegheny Health Network.
Documentation packet checklist
- Chart note with diagnosis (ICD-10 code) and clinical severity markers
- Documented failure of, contraindication to, or intolerance of step-therapy alternatives in HER2/neu Receptor Antagonist
- Prior treatment history including dosing, duration, and reason for discontinuation
- Relevant labs, imaging, or assessment scores supporting medical necessity
- Prescriber attestation linking the FDA-approved indication to the patient's presentation
- Highmark's medical policy URL referenced in the cover letter
Denial scenarios to check against the current policy
These are preparation scenarios, not frequency claims. Use only those supported by the current member-specific source:
- Prior auth on biologics
- PA on advanced imaging
- OON balance bills
TRASTUZUMAB (Herceptin)-specific review scenarios and context
Check whether the current notice cites any of these label-, REMS-, or policy-related scenarios:
- Plan-mandated biosimilar switch mid-treatment
- HER2 IHC 2+ with FISH equivocal — plan demands IHC 3+
- Adjuvant duration beyond 1 year
- Site-of-care reduction
Brand: Herceptin. Reference biologic for HER2-positive breast and gastric cancer. Biosimilars: Kanjinti, Trazimera, Ogivri, Ontruzant, Herzuma. Also a component of Enhertu (trastuzumab deruxtecan, separate molecule) and Kadcyla.
Manufacturer patient-assistance program: Genentech Patient Foundation — relevant when a Highmark denial sticks and the patient needs bridge access while appealing.
How Highmark approaches Biosimilars PAs
For TRASTUZUMAB (ONTRUZANT), check whether the current Highmark Biosimilars policy cites prior auth on biologics. Pharmacy-benefit review for TRASTUZUMAB (ONTRUZANT) at Highmark is routed through Express Scripts. The applicable review clock depends on the member's current product, whether the request is complete and urgent, and governing plan rules. Confirm receipt and timing with Highmark; if denied, use the filing date and route printed on that denial notice. Highmark treats interchangeability designation and prescriber "dispense-as-written" language as the two pivot points for biosimilar-vs-reference disputes. Highmark is domiciled in PA, so unresolved appeals escalate to the PA insurance department's external-review program for fully-insured policies (self-funded ERISA plans route to the DOL EBSA instead).
If the PA is denied
Verify the appeal window and decision clock in the current denial notice and member-specific payer source before relying on either. Submit through the provider portal (https://www.highmark.com/provider) with the same packet plus an applicable, current clinical source supporting TRASTUZUMAB (Herceptin)for the patient's indication.
Contact Highmark
- Provider portal: https://www.highmark.com/provider
Frequently asked questions
What documentation does Highmark need for TRASTUZUMAB (Herceptin) prior auth?
Highmark's typical PA packet for TRASTUZUMAB (Herceptin): (1) chart note documenting the indication and prior-treatment failures, (2) supporting lab/imaging where indicated, (3) prescriber attestation that step-therapy alternatives were tried or contraindicated, (4) FDA-approved indication mapped to ICD-10 diagnosis. For HER2/neu Receptor Antagonist, expect clinical-criteria documentation specific to this class.
What's the turnaround time at Highmark?
Verify the decision clock in the current member-specific payer policy and request receipt. Product type, urgency, state law, and plan terms can change the applicable timing; this page does not supply an operational deadline.
What documentation issues should be checked for TRASTUZUMAB (Herceptin) at Highmark?
Preparation scenarios to check against the current notice and policy include: Prior auth on biologics; PA on advanced imaging; OON balance bills. These are not measured frequency claims. For TRASTUZUMAB (Herceptin), verify whether the actual denial raises step therapy, indication, or another plan-specific criterion before responding.
Can Highmark force a mid-treatment switch from the reference biologic to TRASTUZUMAB (ONTRUZANT)?
Highmark can require biosimilar use at initiation, but mid-treatment forced switches face higher appeal-reversal rates when the chart documents a stable patient, a defined transition-of-care concern, or prescriber "dispense-as-written" intent supported by a clinical rationale (immunogenicity history, nocebo response in prior switches, narrow therapeutic window). Cite the FDA Purple Book interchangeability designation when arguing the switch — interchangeable biosimilars permit pharmacy substitution; non-interchangeable biosimilars do not. Pharmacy-benefit handling is routed through Express Scripts. External-review escalation for Highmark fully-insured policies sits with the PA insurance department.
How do I prep for a peer-to-peer with Highmark on TRASTUZUMAB (Herceptin)?
Lead with the FDA-approved indication and the specific clinical criteria the policy lists. Have the patient's chart open, document number, and policy URL on screen. State your name and credentials, the policy number, the indication, and the documented failures of step-therapy alternatives. Keep notes — if the P2P reviewer overturns, get the decision in writing.
Related PA criteria
Generate the TRASTUZUMAB (Herceptin) PA packet
Open ApprovalHelp — generate a TRASTUZUMAB (Herceptin) prior-auth packet tailored to Highmark's criteria, with prescriber attestation and step-therapy documentation pre-filled.
Get started →Contact: hello@approvalhelp.com